BMO Capital analyst George Farmer raised the price target on Biogen (NASDAQ: BIIB) to $297.00 (from $250.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Biogen (BIIB) PT Raised to $305 at Canaccord GenuityOctober 23, 2019 5:14 AM Increasing unusual put option volume: GNW GDI BIIB GOSS CATM CTVA ODP GMEOctober 23, 2019 4:36 AM Stocks with Implied Volatility MovementOctober 23, 2019 4:24 AM Biogen, Eisai revive plans for Alzheimer's drug, surprising marketOctober 22, 2019 5:08 PM Form 10-Q BIOGEN INC. For: Sep 30October 22, 2019 4:14 PM Biogen (BIIB) ALZ Drug Has 0% Chance of Winning Approval: Raymond James - BloombergOctober 22, 2019 3:50 PM Biogen (BIIB) PT Raised to $310 at JefferiesOctober 22, 2019 1:45 PM Biogen (BIIB) PT Raised to $249 at WedbushOctober 22, 2019 12:44 PM Biogen (BIIB) PT Raised to $296 at StifelOctober 22, 2019 12:11 PM Biogen (BIIB) PT Raised to $334 at Oppenheimer Amid Aducanuma NewsOctober 22, 2019 11:53 AM Increasing unusual option volume: HHC GOSS HOG BIIB SSYS FBHS PBF TGP HCA LLNW October 22, 2019 11:18 AM Increasing unusual put option volume: GOSS CATM BIIB HCA WEC SSYS TRV WPM HOGOctober 22, 2019 9:52 AM Pre-Open 10/22: (BIIB) (STMP) (GNC) Higher (TTS) (TEUM) (HHC) Lower (more...)October 22, 2019 9:30 AM Wall Street slips after rejection of Brexit timetableOctober 22, 2019 7:50 AM Biogen (BIIB) News 'Somewhat Astonishing', Shares Could Trade Back Toward Low-$300s - RBCOctober 22, 2019 7:32 AM Form 8-K BIOGEN INC. For: Oct 22October 22, 2019 7:09 AM Biogen (BIIB) Tops Q3 EPS by 90cOctober 22, 2019 6:53 AM Biogen (BIIB) Surges 18.5% Pre-Market After Announcing Plans to Pursue Regulatory Approval for Aducanumab in Alzheimer’s DiseaseOctober 22, 2019 6:41 AM Biogen (BIIB) Says it Plans Regulatory Filing for Aducanumab in Alzheimer's Disease After Consulting with FDAOctober 22, 2019 6:33 AM Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 StudiesOctober 22, 2019 6:31 AM Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 StudiesOctober 22, 2019 6:30 AM Biogen (BIIB) IV flat into EPS and outlookOctober 21, 2019 10:18 AM